X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/a-small-buyout-deal-gives-a-penny-stock-biotech-a-boost-and-a-second-chance/
https://www.globenewswire.com/news-release/2020/10/28/2115807/0/en/miRagen-Therapeutics-Inc-Announces-Acquisition-of-Viridian-Therapeutics-Inc.html
https://www.globenewswire.com/news-release/2020/10/05/2103829/0/en/miRagen-Announces-Internal-Review-of-Preliminary-Topline-Data-for-the-Phase-2-SOLAR-Clinical-Trial-of-Cobomarsen-in-Patients-with-Cutaneous-T-Cell-Lymphoma-CTCL.html
https://www.fiercebiotech.com/biotech/miragen-coo-takes-wheel-as-company-mulls-strategic-alternatives
https://www.globenewswire.com/news-release/2020/09/14/2093304/0/en/miRagen-Announces-Leadership-Transition-and-Review-of-Strategic-Alternatives.html
http://investors.miragen.com/press-releases/press-release/2020/miRagen-Announces-Results-of-Meeting-With-FDA-Regarding-the-Design-of-Pivotal-Trial-for-Cobomarsen-in-ATLL/default.aspx
https://www.streetinsider.com/Corporate+News/miRagen+Therapeutics+%28MGEN%29+Confirms+Cobomarsen+Receives+Orphan+Drug+Designation+From+U.S.+FDA+for+Treatment+of+T-cell+Lymphoma/17145879.html#:~:text=miRagen%20Therapeutics%2C%20Inc.,treatment%20of%20T%2Dcell%20lymphoma.
https://www.globenewswire.com/news-release/2020/06/22/2051595/0/en/miRagen-Announces-Encouraging-Preclinical-Safety-and-Efficacy-Data-for-its-Next-generation-miR-29-Replacement-Product-Candidate-Intended-for-the-Treatment-of-Idiopathic-Pulmonary-F.html
Market Place
Share 
